tiprankstipranks
Biogen (BIIB)
NASDAQ:BIIB
US Market
BIIB
Biogen
RESEARCH TOOLSreports

Biogen (BIIB) Stock Forecast & Price Target

5,002 Followers
See the Price Targets and Ratings of:

BIIB Analyst Ratings

Moderate Buy
27Ratings
Moderate Buy
11 Buy
15 Hold
1 Sell
Based on 27 analysts giving stock ratings to
Biogen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BIIB Stock 12 Month Forecast

Average Price Target

$209.00
▲(17.85% Upside)
Based on 27 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $209.00 with a high forecast of $275.00 and a low forecast of $150.00. The average price target represents a 17.85% change from the last price of $177.34.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"119":"$119","276":"$276","158.25":"$158.3","197.5":"$197.5","236.75":"$236.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":275,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$275.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":209,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$209.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":150,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$150.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[119,158.25,197.5,236.75,276],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,183.78,190.79692307692306,197.81384615384616,204.83076923076922,211.8476923076923,218.86461538461538,225.88153846153847,232.89846153846153,239.91538461538462,246.9323076923077,253.94923076923078,260.9661538461538,267.9830769230769,{"y":275,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,183.78,185.72,187.66,189.6,191.54,193.48,195.42000000000002,197.36,199.3,201.24,203.18,205.12,207.06,{"y":209,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,183.78,181.18153846153845,178.58307692307693,175.98461538461538,173.38615384615386,170.7876923076923,168.18923076923076,165.59076923076924,162.9923076923077,160.39384615384614,157.79538461538462,155.19692307692307,152.59846153846155,{"y":150,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":132.03,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.63,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.22,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.78,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.99,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.09,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.05,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.78,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$275.00Average Price Target$209.00Lowest Price Target$150.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on BIIB
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$187.57→$214
Buy
20.67%
Upside
Reiterated
04/04/26
Stifel Nicolaus Keeps Their Buy Rating on Biogen (BIIB)
H.C. Wainwright Analyst forecast on BIIB
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$228→$237
Buy
33.64%
Upside
Reiterated
04/02/26
Biogen price target raised to $237 from $228 at H.C. WainwrightBiogen price target raised to $237 from $228 at H.C. Wainwright
Wedbush Analyst forecast on BIIB
Laura Chico
Wedbush
Wedbush
$187→$191
Hold
7.70%
Upside
Reiterated
04/02/26
Wedbush Keeps Their Hold Rating on Biogen (BIIB)
Barclays Analyst forecast on BIIB
Emily Field
Barclays
Barclays
$185
Hold
4.32%
Upside
Reiterated
04/02/26
Analysts Conflicted on These Healthcare Names: Gossamer Bio (NASDAQ: GOSS) and Biogen (NASDAQ: BIIB)
Oppenheimer Analyst forecast on BIIB
Jay Olson
Oppenheimer
Oppenheimer
$250→$275
Buy
55.07%
Upside
Assigned
04/01/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA), Oric Pharmaceuticals (NASDAQ: ORIC) and Biogen (NASDAQ: BIIB)
Canaccord Genuity Analyst forecast on BIIB
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$230→$245
Buy
38.15%
Upside
Reiterated
04/01/26
Biogen (BIIB) Gets a Buy from Canaccord Genuity
Citi Analyst forecast on BIIB
Geoff Meacham
Citi
Citi
$215
Hold
21.24%
Upside
Reiterated
03/31/26
Biogen: Spinraza HD Approval Supports but Does Not Transform Outlook; Leqembi Execution and MS Erosion Keep Rating at Hold
BTIG Analyst forecast on BIIB
Thomas Shrader
BTIG
BTIG
―
Hold
―
Reiterated
03/31/26
Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Biogen (NASDAQ: BIIB) and Vertex Pharmaceuticals (NASDAQ: VRTX)
William Blair Analyst forecast on BIIB
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
03/30/26
Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and Kezar Life Sciences (NASDAQ: KZR)
Needham Analyst forecast on BIIB
Ami Fadia
Needham
Needham
―
Hold
―
Reiterated
03/30/26
Biogen (Litifilimab/Lupus): Encouraging Early Data but Competitive and Clinical Risks Support a Neutral Hold
Bank of America Securities Analyst forecast on BIIB
Jason Zemansky
Bank of America Securities
Bank of America Securities
$207
Hold
16.72%
Upside
Reiterated
03/30/26
Biogen: Incremental Pipeline Progress and Spinraza Update Support Hold Rating Amid Ongoing Uncertainties
BMO Capital Analyst forecast on BIIB
Evan Seigerman
BMO Capital
BMO Capital
$196
Hold
10.52%
Upside
Reiterated
03/30/26
High-dose Spinraza approval, AMETHYST data drivers for Biogen, says BMO CapitalHigh-dose Spinraza approval, AMETHYST data drivers for Biogen, says BMO Capital
TD Cowen Analyst forecast on BIIB
Phil Nadeau
TD Cowen
TD Cowen
$215
Buy
21.24%
Upside
Reiterated
03/30/26
Analysts Offer Insights on Healthcare Companies: Definitive Healthcare Corp (NASDAQ: DH) and Biogen (NASDAQ: BIIB)
Morgan Stanley Analyst forecast on BIIB
Terence Flynn
Morgan Stanley
Morgan Stanley
$190
Hold
7.14%
Upside
Reiterated
03/29/26
Balanced but Constrained Upside: Hold Rating on Biogen as Modest Litifilimab Data Meet Rising Lupus Competition
UBS Analyst forecast on BIIB
Michael Yee
UBS
UBS
$185
Hold
4.32%
Upside
Reiterated
03/29/26
Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and TSURUHA Holdings (Other OTC: TSUSF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on BIIB
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$187.57→$214
Buy
20.67%
Upside
Reiterated
04/04/26
Stifel Nicolaus Keeps Their Buy Rating on Biogen (BIIB)
H.C. Wainwright Analyst forecast on BIIB
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$228→$237
Buy
33.64%
Upside
Reiterated
04/02/26
Biogen price target raised to $237 from $228 at H.C. WainwrightBiogen price target raised to $237 from $228 at H.C. Wainwright
Wedbush Analyst forecast on BIIB
Laura Chico
Wedbush
Wedbush
$187→$191
Hold
7.70%
Upside
Reiterated
04/02/26
Wedbush Keeps Their Hold Rating on Biogen (BIIB)
Barclays Analyst forecast on BIIB
Emily Field
Barclays
Barclays
$185
Hold
4.32%
Upside
Reiterated
04/02/26
Analysts Conflicted on These Healthcare Names: Gossamer Bio (NASDAQ: GOSS) and Biogen (NASDAQ: BIIB)
Oppenheimer Analyst forecast on BIIB
Jay Olson
Oppenheimer
Oppenheimer
$250→$275
Buy
55.07%
Upside
Assigned
04/01/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA), Oric Pharmaceuticals (NASDAQ: ORIC) and Biogen (NASDAQ: BIIB)
Canaccord Genuity Analyst forecast on BIIB
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$230→$245
Buy
38.15%
Upside
Reiterated
04/01/26
Biogen (BIIB) Gets a Buy from Canaccord Genuity
Citi Analyst forecast on BIIB
Geoff Meacham
Citi
Citi
$215
Hold
21.24%
Upside
Reiterated
03/31/26
Biogen: Spinraza HD Approval Supports but Does Not Transform Outlook; Leqembi Execution and MS Erosion Keep Rating at Hold
BTIG Analyst forecast on BIIB
Thomas Shrader
BTIG
BTIG
―
Hold
―
Reiterated
03/31/26
Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Biogen (NASDAQ: BIIB) and Vertex Pharmaceuticals (NASDAQ: VRTX)
William Blair Analyst forecast on BIIB
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
03/30/26
Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and Kezar Life Sciences (NASDAQ: KZR)
Needham Analyst forecast on BIIB
Ami Fadia
Needham
Needham
―
Hold
―
Reiterated
03/30/26
Biogen (Litifilimab/Lupus): Encouraging Early Data but Competitive and Clinical Risks Support a Neutral Hold
Bank of America Securities Analyst forecast on BIIB
Jason Zemansky
Bank of America Securities
Bank of America Securities
$207
Hold
16.72%
Upside
Reiterated
03/30/26
Biogen: Incremental Pipeline Progress and Spinraza Update Support Hold Rating Amid Ongoing Uncertainties
BMO Capital Analyst forecast on BIIB
Evan Seigerman
BMO Capital
BMO Capital
$196
Hold
10.52%
Upside
Reiterated
03/30/26
High-dose Spinraza approval, AMETHYST data drivers for Biogen, says BMO CapitalHigh-dose Spinraza approval, AMETHYST data drivers for Biogen, says BMO Capital
TD Cowen Analyst forecast on BIIB
Phil Nadeau
TD Cowen
TD Cowen
$215
Buy
21.24%
Upside
Reiterated
03/30/26
Analysts Offer Insights on Healthcare Companies: Definitive Healthcare Corp (NASDAQ: DH) and Biogen (NASDAQ: BIIB)
Morgan Stanley Analyst forecast on BIIB
Terence Flynn
Morgan Stanley
Morgan Stanley
$190
Hold
7.14%
Upside
Reiterated
03/29/26
Balanced but Constrained Upside: Hold Rating on Biogen as Modest Litifilimab Data Meet Rising Lupus Competition
UBS Analyst forecast on BIIB
Michael Yee
UBS
UBS
$185
Hold
4.32%
Upside
Reiterated
03/29/26
Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and TSURUHA Holdings (Other OTC: TSUSF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Biogen

3 Months
xxx
Success Rate
19/38 ratings generated profit
50%
Average Return
+0.63%
reiterated a xxx
 rating last month
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +0.63% per trade.
1 Year
Marc GoodmanLeerink Partners
Success Rate
16/35 ratings generated profit
46%
Average Return
+0.82%
reiterated a buy rating 6 months ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 45.71% of your transactions generating a profit, with an average return of +0.82% per trade.
2 Years
xxx
Success Rate
14/35 ratings generated profit
40%
Average Return
-8.31%
reiterated a xxx
 rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of -8.31% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BIIB Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
1
0
0
0
0
Buy
31
18
23
21
17
Hold
23
21
31
36
27
Sell
2
2
2
1
1
Strong Sell
0
0
0
0
0
total
57
41
56
58
45
In the current month, BIIB has received 17 Buy Ratings, 27 Hold Ratings, and 1 Sell Ratings. BIIB average Analyst price target in the past 3 months is 209.00.
Each month's total comprises the sum of three months' worth of ratings.

BIIB Financial Forecast

BIIB Earnings Forecast

Next quarter’s earnings estimate for BIIB is $3.04 with a range of $1.66 to $4.68. The previous quarter’s EPS was $1.99. BIIB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.
Next quarter’s earnings estimate for BIIB is $3.04 with a range of $1.66 to $4.68. The previous quarter’s EPS was $1.99. BIIB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.

BIIB Sales Forecast

Next quarter’s sales forecast for BIIB is $2.25B with a range of $2.13B to $2.43B. The previous quarter’s sales results were $2.18B. BIIB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.
Next quarter’s sales forecast for BIIB is $2.25B with a range of $2.13B to $2.43B. The previous quarter’s sales results were $2.18B. BIIB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.

BIIB Stock Forecast FAQ

What is BIIB’s average 12-month price target, according to analysts?
Based on analyst ratings, Biogen’s 12-month average price target is 209.00.
    What is BIIB’s upside potential, based on the analysts’ average price target?
    Biogen has 17.85% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BIIB a Buy, Sell or Hold?
          Biogen has a consensus rating of Moderate Buy which is based on 11 buy ratings, 15 hold ratings and 1 sell ratings.
            What is Biogen’s price target?
            The average price target for Biogen is 209.00. This is based on 27 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $275.00 ,the lowest forecast is $150.00. The average price target represents 17.85% Increase from the current price of $177.34.
              What do analysts say about Biogen?
              Biogen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 27 Wall Streets Analysts.
                How can I buy shares of BIIB?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.